Surmodics stock rises after FTC indicates no appeal of merger ruling By Investing.com
Surmodics stock rises after FTC indicates no appeal of merger ruling
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
Surmodics stock rises after FTC indicates no appeal of merger ruling
Surmodics reports June cyber incident, restores critical IT systems
SurModics (SRDX) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for some clues.
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics second-quarter fiscal 2025 results show weak performance.